Johns Hopkins ABX Guide
Daclatasvir
INDICATIONS
FDA
FDA
- Treatment of chronic hepatitis C virus (HCV) genotype 1 or 3 infection, in combination with sofosbuvir (SOF).
- Daclatasvir is indicated for treating HIV/HCV co-infected patients in patients with compensated Child-Pugh Class A cirrhosis, decompensated Child-Pugh B or C cirrhosis, and in patients that develop recurrent HCV post-transplant.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
Treatment of HCV genotypes 2, 4.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: October 18, 2022
Citation
Auwaerter, Paul G, and Janessa M Smith. "Daclatasvir." Johns Hopkins ABX Guide, The Johns Hopkins University, 2022. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540654/all/Daclatasvir.
Auwaerter PG, Smith JM. Daclatasvir. Johns Hopkins ABX Guide. The Johns Hopkins University; 2022. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540654/all/Daclatasvir. Accessed October 31, 2024.
Auwaerter, P. G., & Smith, J. M. (2022). Daclatasvir. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540654/all/Daclatasvir
Auwaerter PG, Smith JM. Daclatasvir [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2022. [cited 2024 October 31]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540654/all/Daclatasvir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Daclatasvir
ID - 540654
A1 - Auwaerter,Paul,M.D.
AU - Smith,Janessa,PharmD, BCPS
Y1 - 2022/10/18/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540654/all/Daclatasvir
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
